IPSEN (OTCMKTS:IPSEY) Short Interest Up 286.5% in June

IPSEN (OTCMKTS:IPSEY) saw a significant increase in short interest in the month of June. As of June 15th, there was short interest totaling 143 shares, an increase of 286.5% from the May 31st total of 37 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily volume of 568 shares, the short-interest ratio is presently 0.3 days.

IPSEN Stock Performance

IPSEY remained flat at $46.50 during trading on Monday. 42 shares of the company’s stock were exchanged, compared to its average volume of 565. IPSEN has a 1 year low of $29.05 and a 1 year high of $51.10. The company’s 50 day moving average price is $47.34 and its two-hundred day moving average price is $43.72.

Analysts Set New Price Targets

Several brokerages have recently issued reports on IPSEY. HC Wainwright assumed coverage on shares of IPSEN in a report on Friday, June 5th. They issued a “buy” rating for the company. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of IPSEN in a research note on Thursday, May 14th. Finally, Zacks Research raised IPSEN to a “hold” rating in a research note on Friday, May 29th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold”.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).